ClearPoint Neuro(US:CLPT) ZACKS·2025-11-07 00:16Core Insights - ClearPoint Neuro, Inc. reported a quarterly loss of $0.21 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.20, marking a year-over-year increase from a loss of $0.18 per share [1] - The company generated revenues of $8.86 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 10.5%, but showing an increase from $8.12 million in the same quarter last year [2] - ClearPoint Neuro's stock has increased by approximately 10.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for ClearPoint Neuro is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.19 on revenues of $10.7 million, and for the current fiscal year at -$0.81 on revenues of $38.3 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which ClearPoint Neuro belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]